ArticleFrontiers in immunology2025
Association between Khorana score and prognosis in cancer patients with stage IV treated with immune checkpoint inhibitors ∼ factor analysis in Khorana score related to overall survival.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The Khorana venous thromboembolism risk assessment score (Khorana score) is an established tool for risk stratification of thromboembolism in patients with cancer. There have been few reports on the relation between Khorana score and prognosis in patients after treatment with immune checkpoint inhibitors (ICIs). The present study was performed to evaluate the association between prognosis and Khorana score in patients with stage IV cancer treated with ICIs. Methods: We conducted a retrospective chart survey of patients receiving at least one ICI at Shinshu University Hospital between September 2014 and October 2021. Age, sex, cancer type, body mass index, laboratory data at commencement of treatment, and patient outcomes were obtained from electronic medical records. Khorana score was calculated based on cancer type and biomarkers. Results: The study population consisted of 407 patients (71.0% men) with a median age of 70.0 years (interquartile range [IQR], 63.0-76.0) and a median follow-up of 15.1 months (range, 0.16-72.0). Nivolumab was the most commonly used ICI (60.4%). The median survival time (MST) for all patients was 17.5 months (95% CI, 14.4-20.8). There were significant differences in MST between the low-risk, intermediate-risk and high-risk groups according to Khorana score ( Conclusion: Our results suggested that Khorana score at the start of ICIs treatment was related to prognosis of patients with stage IV cancer. In particular, Hb level < 10 g/dL before commencement of treatment was shown to be an independent risk factor affecting prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.